Pharmacokinetic considerations in the treatment of CNS tumours.
about
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancerALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsImage-guided convection-enhanced delivery platform in the treatment of neurological diseases.Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis studyTissue concentration of systemically administered antineoplastic agents in human brain tumors.Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.Development and validation of a liquid chromatography-tandem mass spectrometry method for topotecan determination in beagle dog plasma and its application in a bioequivalence study.A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrierClinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Preclinical approaches to study the biology and treatment of brain metastases.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme.Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.Drug interactions at the blood-brain barrier: fact or fantasy?Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.Seizures in low- and high-grade gliomas: current management and future outlook.Nanostructure-based drug delivery systems for brain targeting.Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.The Use of Anthracyclines for Therapy of CNS Tumors.Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancerPharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding.VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors.Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.Challenging metastatic breast cancer with the natural defensin PvD1.Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant gene associated with Angelman syndrome
P2860
Q24621947-7CF476EC-0C96-43BB-A654-A8FE6F9BE90CQ26769879-D826C0D4-809E-4748-A27E-3E1B8476DB6CQ31141544-4C89D5B1-8167-4F0F-BF85-B77017E773F4Q33642314-4CF8DA7B-8CB2-48F5-9516-D114257E7A4CQ33844823-7687631E-8D70-4788-87E8-59AE1DF70264Q34393640-6A2F5776-0022-43FD-8B69-AA6E696CD0D2Q34779967-9054D9E6-578B-4AD4-B615-4F810D967C3FQ35030625-75948796-02E5-40F9-8FFA-8F3E14CCE847Q35549714-D1662A8C-C8B2-4DCC-A9DB-113F8980AB35Q35967411-E118CA87-7645-470F-AFC8-D91C12E4E0C7Q36600202-C713BEC0-230B-4A0B-A797-CF67155FD2D4Q36820588-41A8638E-071A-40D8-93E3-9D96296AEA3DQ36936597-FDBDF9C8-98B6-4C81-8B2A-CC94BE8CD595Q37088535-426439F9-CADA-4912-B77E-DE3CCD579F26Q37311185-D2302B83-0879-40CF-ACEA-389B193636E5Q37362486-818714E2-511D-42D5-A4A0-5A0AE8B38DC2Q37579928-B3251B8F-53C9-47A6-B8D1-0FE6BE985663Q37752365-F599FB4F-D1EB-4F77-A3FD-CC68CE76A49FQ37939942-C59479F9-7E6A-46B1-9ED8-34354A0A37C7Q38005196-884F807E-39A5-49E1-BCC0-B7F2602A2DD7Q38181011-4A392C13-28BB-4ABD-8D85-3D86EDE36063Q38407992-536ABF56-DDB1-4553-91A8-0EA09F00760EQ38828319-4BDC8F24-5FA5-4BE3-A329-A91F8EFE1077Q39071253-4D01EE82-B714-49C1-9BD6-C58B910A8B09Q39413633-4317499B-CB08-40C6-AD28-0AF8527FDAD1Q40061354-ED3BCCBD-5E89-4F63-BC22-5C2E7737B3F6Q41933038-B0563F6E-4CBC-4933-94CF-AA32988620B5Q41943293-45AAE7C3-02E9-4BBC-8D3C-38485F6A9624Q47998204-6102CF5E-DB92-4973-862A-1A4478696E22Q48823168-8E120D56-7A3C-487D-98E2-787C668C5C27Q57168803-15444EFF-2F61-4F10-A554-DC28A1C2BECC
P2860
Pharmacokinetic considerations in the treatment of CNS tumours.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacokinetic considerations in the treatment of CNS tumours.
@ast
Pharmacokinetic considerations in the treatment of CNS tumours.
@en
type
label
Pharmacokinetic considerations in the treatment of CNS tumours.
@ast
Pharmacokinetic considerations in the treatment of CNS tumours.
@en
prefLabel
Pharmacokinetic considerations in the treatment of CNS tumours.
@ast
Pharmacokinetic considerations in the treatment of CNS tumours.
@en
P2093
P2860
P1476
Pharmacokinetic considerations in the treatment of CNS tumours.
@en
P2093
Christopher M Waters
Clinton F Stewart
Susannah Motl
Yanli Zhuang
P2860
P304
P356
10.2165/00003088-200645090-00002
P577
2006-01-01T00:00:00Z
P6179
1052202833